Platelets: inflammatory firebugs of vascular walls
Andreas E May1, Peter Seizer, Meinrad Gawaz
1Medizinische Klinik III, Eberhard Karls Universität Tübingen, Otfried-Müller-Strasse 10, D-72076 Tübingen, Germany. andreas.may@med.uni-tuebingen.de
Arteriosclerosis, Thrombosis, and Vascular Biology
|January 5, 2008
Summary
Platelets drive atherosclerosis by triggering inflammation in blood vessels. This review details the molecular mechanisms platelets use to promote this inflammatory vascular disease.
Area of Science:
- Cardiovascular Biology
- Inflammation Research
- Hematology
Background:
- Atherosclerosis is a chronic inflammatory condition affecting arteries.
- Platelets play a critical role in initiating and perpetuating vascular inflammation.
- Understanding platelet-mediated inflammation is key to addressing atherosclerosis.
Purpose of the Study:
- To review the molecular mechanisms by which platelets promote vascular inflammation.
- To highlight key platelet components and pathways involved in atherosclerosis.
- To elucidate the role of platelet interactions in atherogenesis.
Main Methods:
- Literature review of studies on platelet function in atherosclerosis.
- Analysis of molecular pathways involving platelet interactions with vascular cells.
- Synthesis of current knowledge on platelet-driven inflammation.
Main Results:
- Platelets activate leukocytes, endothelial cells, and progenitor cells.
- These interactions trigger autocrine and paracrine inflammatory cascades.
- Specific molecular components and signaling pathways mediate these effects.
Conclusions:
- Platelets are central mediators of vascular inflammation in atherosclerosis.
- Targeting platelet-driven inflammatory pathways may offer therapeutic strategies.
- Further research into platelet molecular mechanisms is crucial for atherosclerosis treatment.
Related Concept Videos
01:22Formation of the Platelet Plug
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
01:38Inflammation
Overview
01:30Inflammatory Response I: Vascular and Cellular
The inflammatory response is the body's defense against infection, injury, or irritation from bacteria, trauma, toxins, or heat. Inflammation helps locate and destroy pathogens and remove damaged tissue elements to heal the body. During this initial phase, fluid, blood products, and nutrients migrate to the injured area, resulting in redness, heat, swelling, ache, and loss of function. Moreover, signs of systemic inflammation include fever, increased WBC count, malaise, anorexia, nausea,...
01:18Structure and Function of Platelets
The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000 platelets, with...
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000 platelets, with...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:16Clot Retraction and Fibrinolysis
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.